Skip to content
AI News HubLIVE
More
Summary only

AI is saving pharma billions in manufacturing and back-office work, just not in the lab

Eli Lilly's digital chief admits that, so far, AI is paying off in pharma everywhere except where the industry hyped it most: drug discovery. Despite billions in investment, there's no proof AI is making clinical trials more successful. Instead, AI's wins have come from manufacturing and back-office tasks, with analysts estimating savings of around $90 billion.

SourceThe DecoderAuthor: Maximilian Schreiner
AI is saving pharma billions in manufacturing and back-office work, just not in the lab
Report an error

The correction channel is not available yet. You can copy the article reference below for later.

Correction instructions

Summary only

Under the source content permission, this page provides an editorial summary, key points, and a link to the original article.

Key points and analysis

Article intelligence

EngineersAdvanced

Key points

  • Eli Lilly's CIO says AI benefits are in manufacturing and back-office, not drug discovery.
  • Recursion, an AI drug discovery pioneer, still has no AI-developed drug on the market after 13 years.
  • Lilly used a digital twin to optimize tirzepatide production, cutting time and boosting output.
  • RBC estimates AI could save the US pharma industry $90 billion over five years.

Highlights and analysis are generated automatically and may contain errors. Check the original source.

More recent stories on this topic · Research